Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 3, 2026Endocrinology Diabetes & MetabolismOpen Access

Switching to evogliptin from other DPP-4 inhibitors is linked to a ~0.5% HbA1c reduction.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does switching to evogliptin improve HbA1c in patients with Type 2 Diabetes Mellitus inadequately controlled on metformin and another DPP-4 inhibitor?

Population

770 patients with Type 2 Diabetes Mellitus and HbA1c ≥ 7.0% who had received metformin plus a DPP-4…

Design

Cohort

Follow-up

24 weeks

Key result

Switching to evogliptin from other DPP-4 inhibitors in patients with type 2 diabetes significantly reduced mean HbA1c by 0.5% at 24 weeks (p < 0.0001).

Authors

JLJie-Eun LeeJHJun Hwa HongSYSung Hoon Yu

Discussion

Loading...

Member takes

Overview

May support evogliptin switch after DPP-4 failure; hypothesis-generating for intra-class heterogeneity, needs RCTs.

Key Points

  • This study aims to assess the effectiveness of evogliptin in patients with type 2 diabetes inadequately controlled by other DPP-4 inhibitors.
  • Follow-up analysis of patients with HbA1c ≥ 7.0% switched to evogliptin after 12 weeks on other DPP-4 inhibitors.
  • Assessment of HbA1c changes at 12 and 24 weeks post-switch.
  • Multivariable linear regression to identify predictors of HbA1c reduction.
  • Mean HbA1c decreased by -0.3% at 12 weeks and -0.5% at 24 weeks (p < 0.0001).
  • In the sitagliptin group, reductions were -0.5% at 12 weeks and -0.6% at 24 weeks (p < 0.0001).
  • At 24 weeks, 25.8% achieved HbA1c < 6.5% and 50.5% achieved HbA1c < 7.0%.

Study Design

Type

Observational (n=770)

Multicenter

Yes

Structured PICO

Does switching to evogliptin improve HbA1c in patients with Type 2 Diabetes Mellitus inadequately controlled on metformin and another DPP-4 inhibitor?

P
Population
770 patients with type 2 diabetes and HbA1c ≥ 7.0% on metformin plus a non-evogliptin DPP-4 inhibitor, switched to evogliptin and followed for 24 weeks.
E
Exposure
Switched to evogliptin
O
Outcome
Changes in HbA1c and target achievement at 12 and 24 weekssurrogate

Main Result

p-value: p=<0.0001

Intraclass therapeutic interchange to evogliptin from other DPP-4 inhibitors significantly reduced HbA1c in patients with type 2 diabetes inadequately controlled on metformin and a different DPP-4 inhibitor.

Limitations

  • Observational nature of the study
  • Lack of a comparator group
  • observational nature of this study
  • lack of a comparator group

Cite This Study

Lee et al. (2026) conducted an observational in Type 2 Diabetes Mellitus (n=770). Evogliptin was evaluated on Change in HbA1c at 24 weeks (p=<0.0001). Switching to evogliptin from other DPP-4 inhibitors in patients with type 2 diabetes significantly reduced mean HbA1c by 0.5% at 24 weeks (p < 0.0001).

synapsesocial.com/papers/6a4754f05c29257aa257a48ehttps://doi.org/10.1002/edm2.70270
View Full Paper
Ask AI
Bookmark
Share